Cleveland BioLabs Protectan CBLB502 Demonstrates Strong Mitigation Of Hematopoietic Damage at 48 Hours Post-Exposure to

BUFFALO, NY, Mar 31 (MARKET WIRE) --
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that recent primate
studies have demonstrated the efficacy of Cleveland BioLabs's Protectan
CBLB502 as a mitigator of hematopoietic damage up to 48 hours post radiation
exposure.

Protectan CBLB502 was administered as a single injection at 48 hours
post-exposure to 6.5 Gy doses of ionizing radiation, which results in
approximately 75% mortality, if untreated (similar to doses received by
Chernobyl firefighters). In the non-human primate model tested, approximately
67% of the Protectan CBLB502-treated animals survived compared to 25% of the
control group. Administration of CBLB502 48 hours post exposure was shown to
increase survival, and have a significantly beneficial effect on platelet levels
while
also reducing the severity of radiation-induced neutropenia.

Protection of civilian populations and war-fighters is of high current
interest
to both the Department of Health and Human Services (HHS) and the Department
of Defense (DoD). On March 6, 2008 the Biomedical Advanced Research and
Development Authority (BARDA), a Department of HHS, published a Broad Agency
Announcement (BAA) soliciting research and development proposals for "Therapies
for
Hematopoietic Syndrome, Bone Marrow Stromal Cell Loss, and Vascular Injury
Resulting from Acute Exposure to Ionizing Radiation."

BARDA seeks to acquire developed medical countermeasures that will be
clinically useful in a civilian medical emergency situation that results from or
involves exposure of a large population to the effects of a nuclear detonation,
a
radiologic dispersive device (such as a dirty bomb), or exposure to
radioactive material with or without combined injury or trauma. Among certain
other criteria, the BAA specified that any medical countermeasures submitted
must
be efficacious when administered at or later than 24 hours after exposure.

The BAA anticipates the award of 5 to 6 three-year contracts, each valued at
$3
to $5 million annually, to be made on or about September 16, 2008. The BARDA
BAA may be accessed from the following URL:
http://www.fbo.gov/spg/HHS/OOS/OASPHEP/BAA%2DBARDA%2D08%2D08/listing.html.

Cleveland BioLabs's Protectan CBLB502 has the ability to replenish normal
hematopoietic profile in non-human primates, as demonstrated by recent
experiments. CBLB502 is a derivative of a microbial protein that reduces injury
from acute stresses by mobilizing several natural cell protecting mechanisms,
including inhibition of programmed cell death (apoptosis), reduction of
oxidative
damage and induction of regeneration promoting cytokines. Potential medical
applications for CBLB502 include reduction of radiotherapy or chemotherapy
side effects in cancer patients.

About Cleveland BioLabs, Inc.

Cleveland BioLabs, Inc. is a drug discovery and development company
leveraging
its proprietary discoveries about programmed cell death to treat cancer and
protect normal tissues from exposure to radiation and other stresses. The
Company has strategic partnerships with the Cleveland Clinic, Roswell Park
Cancer
Institute, ChemBridge Corporation and the Armed Forces Radiobiology Research
Institute. To learn more about Cleveland BioLabs, Inc., please visit the
company's
website at http://www.cbiolabs.com.

This press release contains forward-looking statements within the meaning of
the
Private Securities Litigation Reform Act of 1995. Forward-looking statements
reflect
management's current expectations, as of the date of this press release, and
involve certain risks and uncertainties. The Company's actual results could
differ materially from those anticipated in these forward-looking statements
as a result of various factors. Some of the factors that could cause future
results to materially differ from the recent results or those projected in
forward-looking statements include the "Risk Factors" described in the
Company's periodic filings with the Securities and Exchange Commission.

Contacts:
Rachel Levine
Director Corporate Development & Communications
Cleveland BioLabs, Inc.
T: (646) 284-9439
E: rlevine@cbiolabs.com

Copyright 2008, Market Wire, All rights reserved.

-0-